Mitrovic V, Neuzner J, Husseini H, Volz M, Schlepper M
Kerckhoff-Klinik der Max-Planck-Gesellschaft, Bad Nauheim, F.R.G.
J Cardiovasc Pharmacol. 1989;14 Suppl 1:S40-9.
The characteristics of norepinephrine and epinephrine as well as plasma renin activity, angiotensin II, aldosterone, vasopressin, and atrial natriuretic factor (ANF) were examined in 64 patients (mean age of 52 +/- 16 years) with dilated cardiomyopathy. The findings were grouped according to the NYHA classification and compared with a normal cohort of 38 patients (mean age of 42 +/- 10 years). Furthermore, the influence of different cardioactive substances used in the treatment of cardiac failure was analyzed in more detail. Patients in NYHA class II already demonstrated an increased activity of the sympathicoadrenal, renin-angiotensin-aldosterone system (RAAS), vasopressin, and ANF system. The highest values were found in patients of NYHA class IV. In these patients, norepinephrine was enhanced by a factor of 7, epinephrine by a factor of 2, plasma renin activity by a factor of 7, angiotensin II by a factor of 2.5, aldosterone by a factor of 5, vasopressin by a factor of 1.5, and ANF by a factor of 4 compared with those in normal subjects. The highest correlation coefficient was found for norepinephrine (r = 0.84). The acute application of 1-2 mg/kg of body weight of enoximone in patients with dilated cardiomyopathy (n = 15) resulted only in a significant lowering of the atrial natriuretic factor as an indicator for drug-induced unloading effects (venous pooling). All the parameters showed only a tendency; in none could statistical significance be established. Application of 0.75 mg/kg of body weight of enoximone i.v. in patients with coronary artery disease (n = 17) has no direct influence either on the sympathoadrenal, the ANF, or the prostaglandin systems. It could be demonstrated that the mode of medical treatment influences the parameters of vasoconstrictor systems in different ways.
对64例(平均年龄52±16岁)扩张型心肌病患者的去甲肾上腺素、肾上腺素以及血浆肾素活性、血管紧张素II、醛固酮、血管加压素和心房利钠因子(ANF)的特征进行了研究。研究结果根据纽约心脏协会(NYHA)分级进行分组,并与38例(平均年龄42±10岁)正常对照人群进行比较。此外,还更详细地分析了用于治疗心力衰竭的不同心活性物质的影响。NYHA II级患者已表现出交感肾上腺、肾素 - 血管紧张素 - 醛固酮系统(RAAS)、血管加压素和ANF系统活性增加。NYHA IV级患者的值最高。与正常受试者相比,这些患者的去甲肾上腺素增加了7倍,肾上腺素增加了2倍,血浆肾素活性增加了7倍,血管紧张素II增加了2.5倍,醛固酮增加了5倍,血管加压素增加了1.5倍,ANF增加了4倍。去甲肾上腺素的相关系数最高(r = 0.84)。对15例扩张型心肌病患者静脉注射1 - 2 mg/kg体重的依诺昔酮,仅导致作为药物诱导的卸载效应(静脉淤血)指标的心房利钠因子显著降低。所有参数仅显示出一种趋势;均未建立统计学意义。对17例冠状动脉疾病患者静脉注射0.75 mg/kg体重的依诺昔酮,对交感肾上腺、ANF或前列腺素系统均无直接影响。可以证明,药物治疗方式以不同方式影响血管收缩系统的参数。